Temozolomide: How It Treats Brain Cancer & Side Effects

Temozolomide is an oral chemotherapy drug that works by damaging the DNA of rapidly dividing cancer cells, and it remains the backbone of treatment for glioblastoma, the most common and aggressive primary brain tumor in adults. A landmark trial published in 2005 showed that adding temozolomide to radiation therapy extended median survival from about 12 months to roughly 14.6 months and more than doubled the proportion of patients alive at two years. Those numbers sound modest, but in glioblastoma they represented a genuine shift in the standard of care. The drug’s effectiveness, its limitations, and its side effects all trace back to the same chemistry: how it modifies DNA and how well the tumor can repair the damage.

How Temozolomide Damages Tumor DNA

Temozolomide is a prodrug, meaning it converts into its active form inside the body. Once absorbed, it breaks down at physiological pH into a reactive compound called MTIC, which tags DNA with small chemical groups called methyl marks. Most of these marks land on positions that cells can repair fairly easily, but a fraction end up at a specific spot on the guanine base known as O6. That O6-methylguanine lesion is the one that matters most for killing cancer cells.

When a cell tries to copy its DNA with that O6-methylguanine sitting there, the replication machinery pairs the wrong base opposite it. The cell’s mismatch repair system recognizes the error but cannot fix the underlying lesion, so it repeatedly tries and fails, eventually generating breaks in both strands of the DNA. Those double-strand breaks trigger cell death pathways, including programmed cell death and a state of permanent growth arrest called senescence.¹ This mechanism explains why temozolomide does not kill cells immediately. The damage only becomes lethal after the cell attempts to divide, which is why the drug disproportionately affects fast-growing tumor cells.

Crossing the Blood-Brain Barrier

One of temozolomide’s practical advantages is that it reaches the brain after being swallowed as a capsule. The blood-brain barrier, a tightly sealed lining of blood vessels that blocks most drugs from entering brain tissue, does allow temozolomide through, though not perfectly. Research in mice has shown that efflux pumps in the barrier actively push temozolomide back out, limiting how much actually reaches brain tissue. When those pumps were genetically deleted or blocked with a chemical inhibitor, brain penetration of temozolomide increased by about 50% without changing drug levels in the rest of the body.² This finding matters because it suggests the drug’s ceiling of effectiveness in the brain might be pushed higher if those pumps could be safely inhibited in patients.

The ability to cross the blood-brain barrier also makes temozolomide useful for brain metastases from cancers that started elsewhere in the body, such as melanoma or lung cancer. A review of 21 clinical trials found that temozolomide as a single agent had a modest effect on brain metastases, but combining it with whole-brain radiation or other drugs showed more encouraging results.³

The Standard Treatment Protocol

The current standard of care for newly diagnosed glioblastoma is often called the Stupp protocol, after the lead author of the trial that established it. After surgery to remove as much tumor as safely possible, patients receive six weeks of daily radiation therapy with a low daily dose of temozolomide, followed by six monthly cycles of temozolomide at a higher dose taken five days out of every 28. That trial, published in the New England Journal of Medicine, showed median overall survival of 14.6 months with the combination versus 12.1 months with radiation alone, and the two-year survival rate rose from about 10% to roughly 27%.⁴

Temozolomide also holds an approval for recurrent anaplastic astrocytoma, a somewhat less aggressive brain tumor. A large phase II trial in that setting showed a response rate of 35% and nearly half the patients remained progression-free at six months, which led to accelerated regulatory approval.⁵

Why MGMT Methylation Matters So Much

Not every glioblastoma responds equally to temozolomide, and the single biggest predictor is the status of a gene called MGMT. This gene encodes a repair enzyme whose sole job is to strip methyl groups off that critical O6 position on guanine, essentially undoing temozolomide’s most important damage before it can become lethal. When the MGMT gene’s promoter region is chemically silenced through a process called methylation, the tumor produces less of this repair enzyme and is more vulnerable to the drug.

In the companion paper to the Stupp trial, patients whose tumors had a methylated MGMT promoter and who received temozolomide plus radiation had a median survival of 21.7 months, compared with 15.3 months for radiation alone. In patients without MGMT methylation, the survival difference was smaller and not statistically significant.⁶ A regional cohort study later added nuance to this picture by showing that the degree of methylation also matters: patients with high levels of MGMT methylation derived greater survival benefit than those with low levels.⁷

Roughly half of glioblastoma patients have unmethylated MGMT promoters, meaning the standard temozolomide regimen is less likely to help them significantly.⁸ This has generated considerable debate about whether those patients should receive temozolomide at all, or whether alternative approaches should be tried. In practice, most still receive it because the alternatives are limited, but clinical trials increasingly stratify patients by MGMT status to test whether different drugs might work better for the unmethylated group.

Common Side Effects During Treatment

Temozolomide is classified as moderately emetogenic, meaning it often causes nausea without always causing actual vomiting. In one large audit of patients on the standard regimen, the overall incidence of nausea was 25% and vomiting was about 7%.⁹ Anti-nausea drugs given before each dose can prevent symptoms in most patients. A phase II study of one such drug, palonosetron, found that over 90% of glioblastoma patients on temozolomide achieved complete control of vomiting over the full monitoring period.¹⁰

Fatigue is another common complaint and can be difficult to separate from the effects of radiation, the brain tumor itself, and steroid medications that many patients take simultaneously. Constipation, headache, and loss of appetite round out the most frequently reported day-to-day side effects.

Blood Count Drops and Serious Hematologic Events

Temozolomide suppresses the bone marrow, which means it can lower white blood cell, red blood cell, and platelet counts. Mild drops in lymphocyte counts are nearly universal during treatment and are usually manageable with dose adjustments. However, more severe hematologic events do occur. An analysis of adverse event reports submitted to the FDA’s MedWatch system identified 112 cases of major blood-related complications among temozolomide-treated patients, including 76 cases of aplastic anemia or aplasia and 17 cases of leukemia. Of the 44 deaths reported in that dataset, 32 were attributed to the blood-related event itself.¹¹ These severe events are uncommon relative to the large number of patients treated with the drug, but they underscore the importance of regular blood count monitoring throughout therapy.

Infection Risk and Pneumocystis Prophylaxis

The drop in lymphocytes during the radiation-plus-temozolomide phase creates a real risk of opportunistic infections, particularly Pneumocystis jirovecii pneumonia (PCP), a lung infection that typically affects people with weakened immune systems. The temozolomide product label recommends preventive treatment against PCP during the concurrent phase of therapy.¹² The most common preventive agent is trimethoprim-sulfamethoxazole, taken three times a week.

Risk is not uniform across all patients. Those receiving the daily concurrent dosing phase, those on higher corticosteroid doses, and those on dose-dense temozolomide schedules face higher risk than patients in the monthly adjuvant phase alone.¹³ Some institutions have historically not given routine PCP prophylaxis to all temozolomide patients, citing the low absolute incidence, but most neuro-oncology guidelines now favor it at least during the concurrent chemoradiation phase.¹⁴

Late Toxicity and Secondary Blood Cancers

Because temozolomide is an alkylating agent, it carries a long-term risk of causing therapy-related myelodysplastic syndrome (a bone marrow disorder) or therapy-related acute myeloid leukemia. These secondary cancers are rare but serious. Case reports and reviews suggest that the cumulative dose threshold at which risk increases may be around 18,000 to 20,000 mg per square meter of body surface area.¹⁵

The concern has grown as more patients receive extended temozolomide courses beyond the standard six adjuvant cycles, and as patients with lower-grade gliomas who have longer expected survival receive the drug. These are patients who live long enough for a secondary cancer to develop, which is an ironic consequence of better tumor control.¹⁶ This risk is one reason why indefinite temozolomide continuation is generally discouraged.

Drug Resistance and Hypermutation

Temozolomide can, paradoxically, make some tumors more aggressive when they recur. In a study of low-grade astrocytomas treated with temozolomide, six of ten tumors developed what is called hypermutation, accumulating thousands of new coding mutations that were absent in the original tumor. These mutations bore the chemical signature of temozolomide-induced damage. All six hypermutated tumors transformed into glioblastoma and had acquired new defects in mismatch repair genes, the very genes whose function is required for temozolomide to work.¹⁷ In other words, the drug’s mutagenic activity can sometimes drive the evolution of a more resistant and more dangerous tumor.

This is one of the sharpest unresolved dilemmas in neuro-oncology. Temozolomide extends survival for most glioblastoma patients, but in some low-grade glioma patients who might survive for years, the cumulative exposure may accelerate progression. There is no reliable way yet to predict whose tumor will hypermutate.

Dose-Dense Schedules Did Not Help

Researchers tested whether giving temozolomide more intensively, on a dose-dense schedule (21 days out of every 28 instead of 5), would improve outcomes by depleting the MGMT repair enzyme more thoroughly. A randomized phase III trial found no benefit: median overall survival was 14.9 months with the standard schedule versus 16.6 months with dose-dense dosing, a difference that was not statistically significant. The dose-dense arm did produce significantly more severe toxicity, with grade 3 or higher adverse events in 53% of patients versus 34%.¹⁸ A companion quality-of-life analysis confirmed that patients on the dose-dense arm had greater deterioration in global health and motor function, as well as higher symptom burden.¹⁹ The standard five-day schedule remains the accepted approach.

Tumor-Treating Fields as a Combination Partner

The most notable addition to the temozolomide regimen in recent years is tumor-treating fields (TTFields), a device worn on the scalp that delivers low-intensity alternating electric fields to disrupt cell division. A randomized trial found that adding TTFields to maintenance temozolomide extended median overall survival to about 21 months, compared with 16 months for temozolomide alone.²⁰ The combination is now part of the recommended standard of care in many guidelines, though the requirement to wear the device for most of each day is a significant practical burden.

PARP Inhibitors and Overcoming Resistance

One of the most actively explored strategies for boosting temozolomide’s effectiveness involves PARP inhibitors, drugs originally developed for breast and ovarian cancers. In glioblastoma cell lines, adding the PARP inhibitor olaparib to temozolomide increased cell killing regardless of whether the tumor’s MGMT promoter was methylated.²¹ Even more intriguing, PARP inhibitors appeared to restore temozolomide sensitivity in glioblastoma cells that had lost mismatch repair function, which is one of the main routes tumors use to become resistant.²² These findings are still in the preclinical and early clinical-trial stages, but they represent one of the more promising avenues for patients whose tumors do not respond to temozolomide alone.

Temozolomide Beyond Brain Cancer

Though temozolomide is most associated with brain tumors, it has carved out a role in treating neuroendocrine tumors, particularly those arising in the pancreas. A randomized phase III trial found that combining temozolomide with capecitabine (another oral chemotherapy) in advanced pancreatic neuroendocrine tumors produced a median progression-free survival of about 23 months, compared with roughly 14 months for temozolomide alone.²³ A meta-analysis of the capecitabine-temozolomide combination across various neuroendocrine tumor types reported a disease control rate of about 73%.²⁴ Response rates appear to differ by tumor grade, with high-grade neuroendocrine tumors responding considerably better than lower-grade ones.²⁵

The Disappointing Results in Children

One area where temozolomide has not replicated adult success is pediatric high-grade gliomas. Despite the biological similarities between these tumors in children and adults, a Children’s Oncology Group trial found no improvement in event-free survival when temozolomide was added to radiation in children with high-grade astrocytomas. The three-year event-free survival rate was just 11%, and the three-year overall survival was 22%.²⁶ Overexpression of the MGMT repair enzyme was particularly common in the pediatric tumors and was linked to worse outcomes. Broader reviews of the pediatric literature have confirmed that decades of temozolomide use in children have not demonstrated the same survival benefit seen in adults.²⁷ This has pushed pediatric neuro-oncology toward exploring immunotherapies and targeted agents instead.

Focused Ultrasound and Improving Drug Delivery

One of the practical limits of temozolomide is that even though it crosses the blood-brain barrier, it does not do so in concentrations that maximize tumor killing, especially in infiltrative regions where the barrier remains relatively intact. Focused ultrasound is an emerging technique that uses sound waves combined with microbubbles injected into the bloodstream to temporarily open the barrier in targeted brain regions. In preclinical glioblastoma models, combining focused ultrasound with temozolomide increased the drug’s concentration in cerebrospinal fluid from about 23% to 39% of plasma levels, slowed tumor growth, and extended survival compared with temozolomide alone.²⁸ A more recent study using patient-derived tumor models in mice confirmed that the combination suppressed tumor growth and improved survival, with the strongest benefits seen when ultrasound was applied early before the tumor developed its own leaky blood vessels.²⁹ Human trials of focused ultrasound with various chemotherapy agents are underway, though this approach is not yet part of standard care.

Effects on Memory and Thinking

Patients and families understandably worry that a drug designed to damage DNA in the brain might also harm cognitive function. Separating drug effects from those of the tumor, surgery, radiation, seizures, and steroids is extremely difficult. One of the cleaner comparisons came from a European trial in low-grade glioma patients randomized to either radiation or temozolomide alone. Memory testing over time showed no significant difference between the two groups in immediate word recall, suggesting that temozolomide was not causing disproportionate memory decline compared with radiation at the group level.³⁰ That does not mean temozolomide is free of cognitive effects, but it does suggest the drug is not adding a dramatic cognitive toll on top of what radiation or the tumor itself causes.